search
English Bewerken
search EN

Prof. dr. ir. W.G. (Wim) Goettsch

Hoogleraar 
Bètawetenschappen
Farmaceutische wetenschappen
Pharmacoepi. and Clinical Pharmacol.
Pharmacoepi. and Clinical Pharmacol.
 
Bètawetenschappen
Farmaceutische wetenschappen
Pharmacoepi. and Clinical Pharmacol.
Pharmacoepi. and Clinical Pharmacol.
David de Wiedgebouw
Universiteitsweg 99
3584 CG Utrecht

Prof. dr. ir. W.G. (Wim) Goettsch

Hoogleraar
Pharmacoepi. and Clinical Pharmacol.
Pharmacoepi. and Clinical Pharmacol.
030 253 4775
w.g.goettsch@uu.nl
Profiel CV Publicaties Onderzoek Nevenwerkzaamheden Contact
Profiel CV Publicaties Onderzoek Nevenwerkzaamheden Contact
Expertises
Onderzoeksthema's

Publicaties

2024

Wetenschappelijke publicaties

Jiu, L., Wang, J., Versteeg, J.-W., Zhang, Y., Liu, L., Somolinos-Simón, F. J., Tapia-Galisteo, J., García-Sáez, G., Hogervorst, M. A., Li, X., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). Roadmap to Innovation of HTA Methods (IHTAM): insights from three case studies of quantitative methods. International Journal of Technology Assessment in Health Care, 40(1), 1-10. Article e49. https://doi.org/10.1017/S0266462324000564
https://research-portal.uu.nl/ws/files/245634113/roadmap-to-innovation-of-hta-methods-ihtam-insights-from-three-case-studies-of-quantitative-methods.pdf
Brinkhuis, F., Ruof, J., Ham, H. V. D., Gianfrate, F., Strammiello, V., Berntgen, M., Pavlovic, M., Mol, P. G. M., Wasem, J., Dyck, W. V., Cardone, A., Dierks, C., Schiel, A., Solà-Morales, O., Goettsch, W., & Julian, E. (2024). Evaluating progress towards implementation of the European HTA Regulation: Insights generated from the European Access Academy's multi-stakeholder survey. Health Policy and Technology, 13(5), Article 100930. https://doi.org/10.1016/j.hlpt.2024.100930
https://research-portal.uu.nl/ws/files/246264629/1-s2.0-S2211883724000935-main.pdf
Callenbach, M. H. E., Vreman, R. A., Leopold, C., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability. PharmacoEconomics. Advance online publication. https://doi.org/10.1007/s40273-024-01433-4
Hogervorst, M. A., Soman, K. V., Gardarsdottir, H., Goettsch, W. G., & Bloem, L. T. (2024). Analytical Methods for Comparing Uncontrolled Trials with External Controls from Real-World Data: a Systematic Literature Review and Comparison to European Regulatory and Health Technology Assessment Practice. Value in Health. Advance online publication. https://doi.org/10.1016/j.jval.2024.08.002
Schoenmakers, D. H., van den Berg, S., Timmers, L., Adang, L. A., Bäumer, T., Bosch, A., van de Casteele, M., Datema, M. R., Dekker, H., Donnelly, C., Driessens, M. H. E., Graessner, H., Greger, V., Haddad, T., Höglinger, G. U., van den Hout, H., Jonker, C., Langeveld, M., Lambert, L. J., ... Wolf, N. I. (2024). Framework for Multistakeholder Patient Registries in the Field of Rare Diseases: Focus on Neurogenetic Diseases. Neurology, 103(6), Article e209743. https://doi.org/10.1212/WNL.0000000000209743
https://research-portal.uu.nl/ws/files/237996032/schoenmakers-et-al-2024-framework-for-multistakeholder-patient-registries-in-the-field-of-rare-diseases.pdf
Julian, E., Solà-Morales, O., Garcia, M. J., Brinkhuis, F., Pavlovic, M., Martín-Saborido, C., Doeswijk, R., Giuliani, R., Willemsen, A., Goettsch, W., Wörmann, B., Dafni, U., Bucher, H. C., Pérez-Valderrama, B., Bernardini, R., Gianfrate, F., Uyl-de Groot, C. A., & Ruof, J. (2024). The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and Survey of the European Access Academy. Journal of market access & health policy, 12(3), 128-143. https://doi.org/10.3390/jmahp12030011
https://research-portal.uu.nl/ws/files/234649588/jmahp-12-00011.pdf
Versteeg, J.-W., Vreman, R., Mantel-Teeuwisse, A., & Goettsch, W. (2024). Uncertainty In Long-term Relative Effectiveness Of Medicines In Health Technology Assessment: Comparing Assessments Of Medicines For Spinal Muscular Atrophy, Cystic Fibrosis, And Hypercholesterolemia. Value in Health, 27(10), 1358-1366. https://doi.org/10.1016/j.jval.2024.05.023
https://research-portal.uu.nl/ws/files/241481907/PIIS1098301524027414.pdf
Brinkhuis, F., Julian, E., van den Ham, H., Gianfrate, F., Strammiello, V., Berntgen, M., Pavlovic, M., Mol, P., Wasem, J., Van Dyck, W., Cardone, A., Dierks, C., Schiel, A., Bernardini, R., Solà-Morales, O., Ruof, J., & Goettsch, W. (2024). Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy. Health Research Policy and Systems, 22(1), Article 74. https://doi.org/10.1186/s12961-024-01154-2
https://research-portal.uu.nl/ws/files/229947272/s12961-024-01154-2.pdf
Callenbach, M. H. E., Goettsch, W. G., Mantel-Teeuwisse, A. K., & Trusheim, M. (2024). Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity. Drug Discovery Today, 29(7), Article 104048. https://doi.org/10.1016/j.drudis.2024.104048
https://research-portal.uu.nl/ws/files/228258111/1-s2.0-S1359644624001739-main.pdf
Callenbach, M. H. E., Schoenmakers, D., Vreman, R. A., Vijgen, S., Timmers, L., Hollak, C. E. M., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). Illustrating the financial consequences of outcome-based payment models from a payers perspective- the case of autologous gene therapy atidarsagene autotemcel (Libmeldy®). Value in Health, 27(8), 1046-1057. https://doi.org/10.1016/j.jval.2024.05.010
https://research-portal.uu.nl/ws/files/234906666/PIIS1098301524023702.pdf
Hogervorst, M. A., van Hattem, C. C., Sonke, G. S., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Bloem, L. T. (2024). Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned. Drug Discovery Today, 29(7), Article 104031. https://doi.org/10.1016/j.drudis.2024.104031
https://dspace.library.uu.nl/bitstream/handle/1874/452776/1-s2.0-S1359644624001569-main.pdf?sequence=1
Pichler, F. B., Boysen, M., Mittmann, N., Gilardino, R., Bruce, A., Bond, K., Vreman, R. A., Largeron, N., Banhazi, J., Ollendorf, D. A., Jain, M., Upadhyaya, S., & Goettsch, W. G. (2024). An operationalization framework for lifecycle HTA. International Journal of Technology Assessment in Health Care, 40(1), Article e45. https://doi.org/10.1017/S0266462324000199
Pichler, F. B., Boysen, M., Mittmann, N., Gilardino, R., Bruce, A., Bond, K., Vreman, R. A., Largeron, N., Banhazi, J., Ollendorf, D. A., Jain, M., Upadhyaya, S., & Goettsch, W. G. (2024). Lifecycle HTA: Promising applications and a framework for implementation. International Journal of Technology Assessment in Health Care, 40(1), Article e50. https://doi.org/10.1017/S0266462324000187
https://research-portal.uu.nl/ws/files/244258573/lifecycle-hta-promising-applications-and-a-framework-for-implementation-an-htai-global-policy-forum-task-force-report.pdf
Shea, B., Pardo, J. P., Grosskleg, S., Beaton, D. E., Conaghan, P., Goettsch, W., Hofstetter, C., Maxwell, L., Musaus, J., Ollendorf, D., Schultz, G., Stevens, R., Strand, V., Tugwell, P., Williamson, P., Tunis, S., & Simon, L. S. (2024). Increasing uptake through collaboration in the development of core outcome sets: Lessons learned at OMERACT 2023. Seminars in Arthritis and Rheumatism, 66, Article 152438. https://doi.org/10.1016/j.semarthrit.2024.152438
https://dspace.library.uu.nl/bitstream/handle/1874/437747/1-s2.0-S0049017224000787-main.pdf?sequence=1
Desmet, T., Julian, E., Van Dyck, W., Huys, I., Simoens, S., Giuliani, R., Toumi, M., Dierks, C., Dierks, J., Cardone, A., Houÿez, F., Pavlovic, M., Berntgen, M., Mol, P., Schiel, A., Goettsch, W., Gianfrate, F., Capri, S., Ryan, J., ... Ruof, J. (2024). An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators. Journal of market access & health policy, 12(1), 21-34. https://doi.org/10.3390/jmahp12010004
https://research-portal.uu.nl/ws/files/236351168/jmahp-12-00004.pdf
Abraham, K., Kvamme, I., Magrin Sammut, S., de Vries, S., Formosa, T., Dupree, R., Corro Ramos, I., Goettsch, W., & Franken, M. (2024). A blueprint for health technology assessment capacity building: lessons learned from Malta. International Journal of Technology Assessment in Health Care, 40(1), Article e11. https://doi.org/10.1017/S0266462324000072
https://dspace.library.uu.nl/bitstream/handle/1874/437213/a-blueprint-for-health-technology-assessment-capacity-building-lessons-learned-from-malta.pdf?sequence=1
Jiu, L., Wang, J., Javier Somolinos-Simón, F., Tapia-Galisteo, J., García-Sáez, G., Hernando, M., Li, X., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). A literature review of quality assessment and applicability to HTA of risk prediction models of coronary heart disease in patients with diabetes. Diabetes Research and Clinical Practice, 209, Article 111574. https://doi.org/10.1016/j.diabres.2024.111574
https://dspace.library.uu.nl/bitstream/handle/1874/437234/1-s2.0-S0168822724000573-main.pdf?sequence=1
Brinkhuis, F., Goettsch, W. G., Mantel - Teeuwisse, A., & Bloem, L. T. (2024). High cost oncology drugs without proof of added benefit are burdening health systems. The BMJ, 384, Article q511. https://doi.org/10.1136/bmj.q511
https://dspace.library.uu.nl/bitstream/handle/1874/437614/bmj.q511.full.pdf?sequence=1
Brinkhuis, F., Goettsch, W. G., Mantel - Teeuwisse, A., & Bloem, L. T. (2024). Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study. The BMJ, 384, Article e077391. https://doi.org/10.1136/bmj-2023-077391
https://dspace.library.uu.nl/bitstream/handle/1874/437211/bmj-2023-077391.full.pdf?sequence=1
Jiu, L., Hartog, M., Wang, J., Vreman, R. A., Klungel, O. H., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). Tools for assessing quality of studies investigating health interventions using real-world data: a literature review and content analysis. BMJ Open, 14(2), Article e075173. https://doi.org/10.1136/bmjopen-2023-075173
https://dspace.library.uu.nl/bitstream/handle/1874/437819/e075173.full.pdf?sequence=1
Werkman, N. C. C., García-Sáez, G., Nielen, J. T. H., Tapia-Galisteo, J., Somolinos-Simón, F. J., Hernando, M. E., Wang, J., Jiu, L., Goettsch, W. G., van der Kallen, C. J. H., Koster, A., Schalkwijk, C. G., de Vries, H., de Vries, N. K., Eussen, S. J. P. M., Driessen, J. H. M., & Stehouwer, C. D. A. (2024). Disease severity-based subgrouping of type 2 diabetes does not parallel differences in quality of life: the Maastricht Study. Diabetologia, 67(4), 690-702. https://doi.org/10.1007/s00125-023-06082-4
https://dspace.library.uu.nl/bitstream/handle/1874/437529/s00125-023-06082-4.pdf?sequence=1
Trials@Home Consortium (2024). Opportunities and challenges for decentralized clinical trial approaches: European health technology assessment perspective. Value in Health, 27(3), 294-300. https://doi.org/10.1016/j.jval.2023.11.006
https://dspace.library.uu.nl/bitstream/handle/1874/437954/PIIS1098301523061971.pdf?sequence=1
Kaló, Z., Niewada, M., Bereczky, T., Goettsch, W., Vreman, R. A., Xoxi, E., Trusheim, M., Callenbach, M. H. E., Nagy, L., & Simoens, S. (2024). Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries. Expert Review of Pharmacoeconomics and Outcomes Research, 24(2), 181-187. https://doi.org/10.1080/14737167.2023.2282680
https://dspace.library.uu.nl/bitstream/handle/1874/438025/Importance_of_aligning_the_implementation_of_new_payment_models_for_innovative_pharmaceuticals_in_European_countries.pdf?sequence=1

2023

Wetenschappelijke publicaties

Hogervorst, M., Vreman, R. A., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Kesselheim, A. S. (2023). Evolving Pico Characteristics in the Early Oncology Treatment Lifecycle: Differences From Trials to Treatment Guidelines. Value in Health, 26(6), S218-S219. https://doi.org/10.1016/j.jval.2023.03.1191
Hogervorst, M. A., Møllebæk, M., Vreman, R. A., Lu, T. A., Wang, J., De Bruin, M. L., Leufkens, H. G. M., Mantel-Teeuwisse, A., & Goettsch, W. (2023). Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts. BMJ Open, 13(8), Article e072309. https://doi.org/10.1136/bmjopen-2023-072309
https://dspace.library.uu.nl/bitstream/handle/1874/432827/e072309.full.pdf?sequence=1
Jakab, I., Dimitrova, M., Houyez, F., Bereczky, T., Fovenyes, M., Maravic, Z., Belina, I., Andriciuc, C., Toth, K., Piniazhko, O., Hren, R., Gutierrez-Ibarluzea, I., Czech, M., Tesar, T., Niewada, M., Lorenzovici, L., Kamusheva, M., Manova, M., Savova, A., ... Kalo, Z. (2023). Recommendations for patient involvement in health technology assessment in Central and Eastern European countries. https://doi.org/10.3389/fpubh.2023.1176200
https://dspace.library.uu.nl/bitstream/handle/1874/432852/fpubh-11-1176200.pdf?sequence=1
Hogervorst, M. A., Vreman, R., Heikkinen, I., Bagchi, I., Gutierrez-Ibarluzea, I., Ryll, B., Eichler, H.-G., Petelos, E., Tunis, S., Sapede, C., Goettsch, W., Janssens, R., Huys, I., Barbier, L., DeJean, D., Strammiello, V., Lingri, D., Goodall, M., Papadaki, M., ... Oortwijn, W. (2023). Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group. International Journal of Technology Assessment in Health Care, 39(1), Article e40. https://doi.org/10.1017/S0266462323000375
https://dspace.library.uu.nl/bitstream/handle/1874/432833/uncertainty-management-in-regulatory-and-health-technology-assessment-decision-making-on-drugs-guidance-of-the-htai-dia-working-group.pdf?sequence=1
Zemplényi, A., Tachkov, K., Balkanyi, L., Németh, B., Petykó, Z. I., Petrova, G., Czech, M., Dawoud, D., Goettsch, W., Gutierrez Ibarluzea, I., Hren, R., Knies, S., Lorenzovici, L., Maravic, Z., Piniazhko, O., Savova, A., Manova, M., Tesar, T., Zerovnik, S., & Kaló, Z. (2023). Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment. Frontiers in Public Health, 11, Article 1088121. https://doi.org/10.3389/fpubh.2023.1088121
https://dspace.library.uu.nl/bitstream/handle/1874/434154/fpubh-11-1088121.pdf?sequence=1
Van Haesendonck, L., Ruof, J., Desmet, T., Van Dyck, W., Simoens, S., Huys, I., Giuliani, R., Toumi, M., Dierks, C., Dierks, J., Cardone, A., Houÿez, F., Pavlovic, M., Berntgen, M., Mol, P. G. M., Schiel, A., Goettsch, W., Gianfrate, F., Capri, S., ... Julian, E. (2023). The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy's multi-stakeholder pre-convention questionnaire. Journal of market access & health policy, 11(1), Article 2217543. https://doi.org/10.1080/20016689.2023.2217543
https://dspace.library.uu.nl/bitstream/handle/1874/434153/The_role_of_stakeholder_involvement_in_the_evolving_EU_HTA_process_Insights_generated_through_the_European_Access_Academy_s_multi-stakeholder_pre-con.pdf?sequence=1
Wang, T., McAuslane, N., Goettsch, W. G., Leufkens, H. G. M., & De Bruin, M. L. (2023). Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement. International Journal of Technology Assessment in Health Care, 39(1), Article e20. https://doi.org/10.1017/S0266462323000144
https://dspace.library.uu.nl/bitstream/handle/1874/434099/regulatory-health-technology-assessment-and-company-interactions-the-current-landscape-and-future-ecosystem-for-drug-development-review-and-reimbursement.pdf?sequence=1
COVID-19 HTA Best-Practice Development Group (2023). Health technology assessment of tests for SARS-CoV-2 and treatments for COVID-19: A proposed approach and best-practice recommendations. International Journal of Technology Assessment in Health Care, 39(1), Article e24. https://doi.org/10.1017/S0266462323000223
https://dspace.library.uu.nl/bitstream/handle/1874/434098/health-technology-assessment-of-tests-for-sars-cov-2-and-treatments-for-covid-19-a-proposed-approach-and-best-practice-recommendations.pdf?sequence=1
Hogervorst, M. A., Vreman, R. A., Zawada, A., Zielińska, M., Dawoud, D. M., de Jong, B. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2023). Synergy between health technology assessments and clinical guidelines for multiple sclerosis. Clinical and Translational Science, 16(5), 835-849. https://doi.org/10.1111/cts.13492
https://dspace.library.uu.nl/bitstream/handle/1874/428425/Clinical_Translational_Sci_2023_Hogervorst_Synergy_between_health_technology_assessments_and_clinical_guidelines_for.pdf?sequence=1
Németh, B., Kamusheva, M., Mitkova, Z., Petykó, Z. I., Zemplényi, A., Dimitrova, M., Tachkov, K., Balkányi, L., Czech, M., Dawoud, D., Goettsch, W., Hren, R., Knies, S., Lorenzovici, L., Maravic, Z., Piniazhko, O., Zerovnik, S., & Kaló, Z. (2023). Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making. Journal of Comparative Effectiveness Research, 12(4), Article e220157. https://doi.org/10.57264/cer-2022-0157
https://dspace.library.uu.nl/bitstream/handle/1874/427602/cer_2022_0157.pdf?sequence=1
Atikeler, E. K., Fasseeh, A. N., Mantel-Teeuwisse, A. K., Caliskan, Z., Oner, Z. G., Kizilay, H., Kalo, Z., & Goettsch, W. (2023). Health technology assessment in Türkiye: Current status and perspectives on future implementation. Health Policy and Technology, 12(1), Article 100701. https://doi.org/10.1016/j.hlpt.2022.100701
https://dspace.library.uu.nl/bitstream/handle/1874/430343/1-s2.0-S2211883722001083-main.pdf?sequence=1
Callenbach, M. H. E., Ádám, L., Vreman, R. A., Németh, B., Kaló, Z., & Goettsch, W. G. (2023). Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook. Drug Discovery Today, 28(1), 1-9. Article 103433. https://doi.org/10.1016/j.drudis.2022.103433
https://dspace.library.uu.nl/bitstream/handle/1874/426992/1_s2.0_S1359644622004263_main.pdf?sequence=1
Wang, S. V., Pottegård, A., Crown, W., Arlett, P., Ashcroft, D. M., Benchimol, E. I., Berger, M. L., Crane, G., Goettsch, W., Hua, W., Kabadi, S., Kern, D. M., Kurz, X., Langan, S., Nonaka, T., Orsini, L., Perez-Gutthann, S., Pinheiro, S., Pratt, N., ... Williams, R. J. (2023). HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force. Pharmacoepidemiology and Drug Safety, 32(1), 44-55. https://doi.org/10.1002/pds.5507
https://dspace.library.uu.nl/bitstream/handle/1874/425637/Pharmacoepidemiology_and_Drug_2022_Wang_HARmonized_Protocol_Template_to_Enhance_Reproducibility_of_hypothesis.pdf?sequence=1

2022

Wetenschappelijke publicaties

Jiu, L., Wang, J., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). To Merge Randomized Controlled Trials and Real-world Evidence with Bayesian Network Meta-regression: A Case Study in Patients with Myelodysplastic Syndromes. Value in Health, 25(12), S354-S354.
Jiu, L., Junfeng, W., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. (2022). The Methodological Quality of Retrospective Observational Studies to Evaluate Glucose Monitoring Systems in Diabetes Patients: A Systematic Review. Value in Health, 25(1), S209-S209.
Hogervorst, M., Mollebaek, M., Vreman, R. A., Wang, J., Mantel-Teeuwisse, A. K., & Goettsch, W. (2022). Building Bridges Between Regulation, Health Technology Assessment and Clinical Guideline Development. Value in Health, 25(12), S233-S234.
Wang, J., Jiu, L., Tapia-Galisteo, J., Somolinos-Somon, F. J., Garcia-Saez, G., Hernando, M. E., & Goettsch, W. (2022). Evaluating Prediction Model Calibration at the Moderate-strong Level Using Patient Subgroups Identified with Clustering Analysis. Value in Health, 25(12), S367-S367.
Jiu, L., Hartog, M. K., Wang, J., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). Applicability of Appraisal Tools of Real-World Evidence in Health Technology Assessment: A Literature Review and Content Analysis. Value in Health, 25(12), S389-S389.
Versteeg, J. W., Hogervorst, M., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Vreman, R. A. (2022). Uncertainty Regarding the Long-term Effectiveness of New Therapies in Health Technology Assessment. Value in Health, 25(12), S305-S305.
Callenbach, M. H. E., Vreman, R. A., Goettsch, W. G., & Mantel-Teeuwisse, A. K. (2022). Payment and Reimbursement Models for Innovative High-priced Hospital Drugs in the Netherlands: A Survey of Stakeholder's Attitudes and Experiences. Value in Health, 25(12), S261-S261.
Callenbach, M. H. E., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs. International Journal of Environmental Research and Public Health, 20(1), Article 340. https://doi.org/10.3390/ijerph20010340
https://dspace.library.uu.nl/bitstream/handle/1874/426534/ijerph_20_00340_v3.pdf?sequence=1
Ádám, I., Callenbach, M., Németh, B., Vreman, R. A., Tollin, C., Pontén, J., Dawoud, D., Elvidge, J., Crabb, N., van Waalwijk van Doorn-Khosrovani, S. B., Pisters-van Roy, A., Vincziczki, Á., Almomani, E., Vajagic, M., Oner, Z. G., Matni, M., Fürst, J., Kahveci, R., Goettsch, W. G., & Kaló, Z. (2022). Outcome-based reimbursement in Central-Eastern Europe and Middle-East. Frontiers in Medicine, 9, 1-11. Article 940886. https://doi.org/10.3389/fmed.2022.940886
https://dspace.library.uu.nl/bitstream/handle/1874/424217/fmed_09_940886.pdf?sequence=1
Wang, S. V., Pottegård, A., Crown, W., Arlett, P., Ashcroft, D. M., Benchimol, E. I., Berger, M. L., Crane, G., Goettsch, W., Hua, W., Kabadi, S., Kern, D. M., Kurz, X., Langan, S., Nonaka, T., Orsini, L., Perez-Gutthann, S., Pinheiro, S., Pratt, N., ... Williams, R. J. (2022). HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force. Value in Health, 25(10), 1663-1672. https://doi.org/10.1016/j.jval.2022.09.001
https://dspace.library.uu.nl/bitstream/handle/1874/424443/1_s2.0_S1098301522021532_main_1_.pdf?sequence=1
Wang, T., McAuslane, N., Goettsch, W. G., Leufkens, H. G. M., & De Bruin, M. L. (2022). Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile. Frontiers in Pharmacology, 13, 1-10. Article 948161. https://doi.org/10.3389/fphar.2022.948161
https://dspace.library.uu.nl/bitstream/handle/1874/424162/fphar_13_948161.pdf?sequence=1
Kotecha, D., Asselbergs, F. W., Achenbach, S., Anker, S. D., Atar, D., Baigent, C., Banerjee, A., Beger, B., Brobert, G., Casadei, B., Ceccarelli, C., Cowie, M. R., Crea, F., Cronin, M., Denaxas, S., Derix, A., Fitzsimons, D., Fredriksson, M., Gale, C. P., ... Grobbee, D. E. (2022). CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research. The BMJ, 378, 1-9. Article e069048. https://doi.org/10.1136/bmj-2021-069048
https://dspace.library.uu.nl/bitstream/handle/1874/424161/bmj_2021_069048.full.pdf?sequence=1
Innovative Medicines Initiative BigData@Heart Consortium, European Society of Cardiology, and CODE-EHR International Consensus Group (2022). CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research. The Lancet Digital Health, 4(10), E757-E764. https://doi.org/10.1016/S2589-7500(22)00151-0
https://dspace.library.uu.nl/bitstream/handle/1874/424160/PIIS2589750022001510.pdf?sequence=1
Adam, I., Callenbach, M., Nemeth, B., Vreman, R. A., Ponten, J., Strbad, T., Dawoud, D., Kostyuk, A., Seyam, A., Nagy, L., Goettsch, W. G., & Kalo, Z. (2022). Delayed payment schemes in Central-Eastern Europe and Middle-East. Frontiers in Medicine, 9, 1-9. Article 940371. https://doi.org/10.3389/fmed.2022.940371
https://dspace.library.uu.nl/bitstream/handle/1874/422668/fmed_09_940371.pdf?sequence=1
Hogervorst, M. A., Pontén, J., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). Real World Data in Health Technology Assessment of Complex Health Technologies. Frontiers in Pharmacology, 13, 1-9. Article 837302. https://doi.org/10.3389/fphar.2022.837302
https://dspace.library.uu.nl/bitstream/handle/1874/422267/fphar_13_837302.pdf?sequence=1
Schoenmakers, D. H., Beerepoot, S., van den Berg, S., Adang, L., Bley, A., Boelens, J.-J., Fumagalli, F., Goettsch, W. G., Grønborg, S., Groeschel, S., van Hasselt, P. M., Hollak, C. E. M., Lindemans, C., Mochel, F., Mol, P. G. M., Sevin, C., Zerem, A., Schöls, L., & Wolf, N. I. (2022). Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi). Orphanet Journal of Rare Diseases, 17(1), 1-14. Article 48. https://doi.org/10.1186/s13023-022-02189-w
https://dspace.library.uu.nl/bitstream/handle/1874/419579/s13023_022_02189_w.pdf?sequence=1
Jiu, L., Hogervorst, M. A., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). Understanding innovation of health technology assessment methods: the IHTAM framework. International Journal of Technology Assessment in Health Care, 38(1), 1-10. Article e16. https://doi.org/10.1017/S0266462322000010
https://dspace.library.uu.nl/bitstream/handle/1874/419402/understanding_innovation_of_health_technology_assessment_methods_the_ihtam_framework.pdf?sequence=1
Vreman, R. A., Strigkos, G., Leufkens, H. G. M., Schünemann, H. J., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). Addressing uncertainty in relative effectiveness assessments by HTA organizations. International Journal of Technology Assessment in Health Care, 38(1), 1-8. Article e17. https://doi.org/10.1017/S026646232100177X
https://dspace.library.uu.nl/bitstream/handle/1874/419401/addressing_uncertainty_in_relative_effectiveness_assessments_by_hta_organizations.pdf?sequence=1
Kalf, R. R. J., Zuidgeest, M., Delnoij, D. M. J., Bouvy, M. L., & Goettsch, W. G. (2022). Bridging health technology assessment and healthcare quality improvement using international consortium of health outcomes measurement standard sets. International Journal of Technology Assessment in Health Care, 38(1), Article e6. https://doi.org/10.1017/S0266462321000520
https://dspace.library.uu.nl/bitstream/handle/1874/419182/bridging_health_technology_assessment_and_healthcare_quality_improvement_using_international_consortium_of_health_outcomes_measurement_standard_sets.pdf?sequence=1
Hogervorst, M. A., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). Reported Challenges in Health Technology Assessment of Complex Health Technologies. Value in Health, 25(6), 992-1001. https://doi.org/10.1016/j.jval.2021.11.1356
https://dspace.library.uu.nl/bitstream/handle/1874/422265/1_s2.0_S1098301521031879_main.pdf?sequence=1
ten Ham, R. M. T., Frederix, G. W. J., Wu, O., Goettsch, W., Leufkens, H. G. M., Klungel, O. H., & Hoekman, J. (2022). Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England. Value in Health, 25(3), 390-399. https://doi.org/10.1016/j.jval.2021.09.012
https://dspace.library.uu.nl/bitstream/handle/1874/419056/1_s2.0_S1098301521017538_main.pdf?sequence=1
Wang, T., McAuslane, N., Gardarsdottir, H., Goettsch, W. G., & Leufkens, H. G. M. (2022). Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agencies. Drug Discovery Today, 27(1), 347-353. https://doi.org/10.1016/j.drudis.2021.09.014
https://dspace.library.uu.nl/bitstream/handle/1874/416184/1_s2.0_S1359644621004086_main.pdf?sequence=1
Vreman, R. A., Bloem, L. T., van Oirschot, S., Hoekman, J., van der Elst, M. E., Leufkens, H. G., Klungel, O. H., Goettsch, W. G., & Mantel-Teeuwisse, A. K. (2022). The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. International Journal of Health Policy and Management, 11(5), 642-650. https://doi.org/10.34172/ijhpm.2020.198
https://dspace.library.uu.nl/bitstream/handle/1874/420563/IJHPM_Volume_11_Issue_5_Pages_642_650.pdf?sequence=1

Overige resultaten

Hogervorst, M., Goettsch, W., Mantel-Teeuwisse, A. K., Bloem, L., & Vreman, R. A. (2022). Uncertainties Around Tumour Agnostic Therapies in Europe: Barriers and Facilitators of Patient Access. Value in Health, 25(12), S266-S266.

2021

Wetenschappelijke publicaties

Kalf, R. R. J., Delnoij, D. M. J., Ryll, B., Bouvy, M. L., & Goettsch, W. G. (2021). Information Patients With Melanoma Spontaneously Report About Health-Related Quality of Life on Web-Based Forums: Case Study. Journal of Medical Internet Research, 23(12), Article e27497. https://doi.org/10.2196/27497
https://dspace.library.uu.nl/bitstream/handle/1874/419042/PDF.pdf?sequence=1
Hong, Y. D., Jansen, J. P., Guerino, J., Berger, M. L., Crown, W., Goettsch, W. G., Mullins, C. D., Willke, R. J., & Orsini, L. S. (2021). Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials. BMC Medicine, 19(1), 1-15. Article 307. https://doi.org/10.1186/s12916-021-02176-1
https://dspace.library.uu.nl/bitstream/handle/1874/415839/s12916_021_02176_1.pdf?sequence=1
Vreman, R. A., Geenen, J. W., Knies, S., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Goettsch, W. G. (2021). Comment on "Deterministic Sensitivity Analysis Under Ignorance". PharmacoEconomics, 39(10), 1199. https://doi.org/10.1007/s40273-021-01086-7
https://dspace.library.uu.nl/bitstream/handle/1874/413013/Vreman2021_Article_CommentOnDeterministicSensitiv.pdf?sequence=1
Eichler, H.-G., Adams, R., Andreassen, E., Arlett, P., van de Casteele, M., Chapman, S. J., Goettsch, W. G., Martinsson, J. L., Llinares-Garcia, J., Nachtnebel, A., Pean, E., Rasi, G., Reksten, T. R., Timmers, L., Vreman, R. A., van de Vijver, I., & Wenzl, M. (2021). Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. International Journal of Technology Assessment in Health Care, 37(1), 1-11. Article e83. https://doi.org/10.1017/S026646232100057X
https://dspace.library.uu.nl/bitstream/handle/1874/412869/exploring_the_opportunities_for_alignment_of_regulatory_postauthorization_requirements_and_data_required_for_performance_based_managed_entry_agreements.pdf?sequence=1
Kamusheva, M., Tachkov, K., Dimitrova, M., Mitkova, Z., García-Sáez, G., Hernando, M. E., Goettsch, W., & Petrova, G. (2021). A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care. Frontiers in Endocrinology, 12, 1-23. Article 636959. https://doi.org/10.3389/fendo.2021.636959
https://dspace.library.uu.nl/bitstream/handle/1874/412691/fendo_12_636959.pdf?sequence=1
Broekhoff, T. F., Sweegers, C. C. G., Krijkamp, E. M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Goettsch, W. G., & Vreman, R. A. (2021). Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios. Value in Health, 24(6), 759-769. https://doi.org/10.1016/j.jval.2020.09.021
https://dspace.library.uu.nl/bitstream/handle/1874/412690/PIIS109830152100053X.pdf?sequence=1
Bloem, L. T., Vreman, R. A., Peeters, N. W. L., Hoekman, J., van der Elst, M. E., Leufkens, H. G. M., Klungel, O. H., Goettsch, W. G., & Mantel-Teeuwisse, A. K. (2021). Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clinical and Translational Science, 14(4), 1566-1577. https://doi.org/10.1111/cts.13027
https://dspace.library.uu.nl/bitstream/handle/1874/412025/cts.13027.pdf?sequence=1
Kalf, R. R. J., Vreman, R. A., Delnoij, D. M. J., Bouvy, M. L., & Goettsch, W. G. (2021). Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines. Pharmacology research & perspectives, 9(2), 1-9. Article e00742. https://doi.org/10.1002/prp2.742
https://dspace.library.uu.nl/bitstream/handle/1874/411769/prp2.742.pdf?sequence=1

2020

Wetenschappelijke publicaties

Orsini, L. S., Monz, B., Mullins, C. D., Van Brunt, D., Daniel, G., Eichler, H. G., Graff, J., Guerino, J., Berger, M., Lederer, N. M., Jonsson, P., Schneeweiss, S., Wang, S. V., Crown, W., Goettsch, W., & Willke, R. J. (2020). Improving transparency to build trust in real-world secondary data studies for hypothesis testing—Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. Pharmacoepidemiology and Drug Safety, 29(11), 1504-1513. https://doi.org/10.1002/pds.5079
https://dspace.library.uu.nl/bitstream/handle/1874/428451/Pharmacoepidemiology_and_Drug_2020_Orsini_Improving_transparency_to_build_trust_in_real_world_secondary_data_studies.pdf?sequence=1
Kolasa, K., Goettsch, W., Petrova, G., & Berler, A. (2020). 'Without data, you're just another person with an opinion'. Expert Review of Pharmacoeconomics and Outcomes Research, 20(2), 147-154. https://doi.org/10.1080/14737167.2020.1751612
https://dspace.library.uu.nl/bitstream/handle/1874/410958/Without_data_you_re_just_another_person_with_an_opinion.pdf?sequence=1
Németh, B., Goettsch, W., Kristensen, F. B., Piniazhko, O., Huić, M., Tesař, T., Atanasijevic, D., Lipska, I., & Kaló, Z. (2020). The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries. Expert Review of Pharmacoeconomics and Outcomes Research, 20(4), 321-329. https://doi.org/10.1080/14737167.2020.1779061
https://dspace.library.uu.nl/bitstream/handle/1874/410957/The_transferability_of_health_technology_assessment_the_European_perspective_with_focus_on_central_and_Eastern_European_countries.pdf?sequence=1
Orsini, L. S., Berger, M., Crown, W., Daniel, G., Eichler, H.-G., Goettsch, W., Graff, J., Guerino, J., Jonsson, P., Lederer, N. M., Monz, B., Mullins, C. D., Schneeweiss, S., Brunt, D. V., Wang, S. V., & Willke, R. J. (2020). Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. Value in Health, 23(9), 1128-1136. https://doi.org/10.1016/j.jval.2020.04.002
https://dspace.library.uu.nl/bitstream/handle/1874/410956/PIIS109830152030190X.pdf?sequence=1
Atikeler, E. K., Leufkens, H. G. M. B., & Goettsch, W. (2020). Access to medicines in Turkey: Evaluation of the process of medicines brought from abroad. International Journal of Technology Assessment in Health Care, 36(6), 585-591. https://doi.org/10.1017/S0266462320000872
https://dspace.library.uu.nl/bitstream/handle/1874/410955/access_to_medicines_in_turkey_evaluation_of_the_process_of_medicines_brought_from_abroad.pdf?sequence=1
Vreman, R. A., Mantel-Teeuwisse, A. K., Hövels, A. M., Leufkens, H. G. M., & Goettsch, W. G. (2020). Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations. Value in Health, 23(1), 10-16. https://doi.org/10.1016/j.jval.2019.07.017
https://dspace.library.uu.nl/bitstream/handle/1874/410897/PIIS1098301519323411.pdf?sequence=1
Vreman, R. A., Naci, H., Goettsch, W. G., Mantel-Teeuwisse, A. K., Schneeweiss, S. G., Leufkens, H. G. M., & Kesselheim, A. S. (2020). Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. Clinical Pharmacology and Therapeutics, 108(2), 350-357. https://doi.org/10.1002/cpt.1835
https://dspace.library.uu.nl/bitstream/handle/1874/410896/cpt.1835.pdf?sequence=1
Vreman, R. A., de Ruijter, A. S., Zawada, A., Tafuri, G., Stoyanova-Beninska, V., O'Connor, D., Naumann-Winter, F., Wolter, F., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Sidiropoulos, I., Larsson, K., & Goettsch, W. G. (2020). Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. Drug Discovery Today, 25(7), 1223-1231. https://doi.org/10.1016/j.drudis.2020.04.012
https://dspace.library.uu.nl/bitstream/handle/1874/410895/1_s2.0_S1359644620301604_main.pdf?sequence=1
Vreman, R. A., Belitser, S. V., Mota, A. T. M., Hövels, A. M., Goettsch, W. G., Roes, K. C. B., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2020). Efficacy gap between phase II and subsequent phase III studies in oncology. British Journal of Clinical Pharmacology, 86(7), 1306-1313. https://doi.org/10.1111/bcp.14237
https://dspace.library.uu.nl/bitstream/handle/1874/410894/bcp.14237.pdf?sequence=1
Vreman, R. A., Broekhoff, T. F., Leufkens, H. G. M., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2020). Application of managed entry agreements for innovative therapies in different settings and combinations: A feasibility analysis. International Journal of Environmental Research and Public Health, 17(22), Article 8309. https://doi.org/10.3390/ijerph17228309
https://dspace.library.uu.nl/bitstream/handle/1874/410889/ijerph_17_08309_v2.pdf?sequence=1
Vreman, R. A., Geenen, J. W., Knies, S., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Goettsch, W. G. (2020). The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. PharmacoEconomics, 39(1), 1-17. https://doi.org/10.1007/s40273-020-00979-3
https://dspace.library.uu.nl/bitstream/handle/1874/410888/Vreman2021_Article_TheApplicationAndImplicationsO.pdf?sequence=1
Wang, T., McAuslane, N., Liberti, L., Gardarsdottir, H., Goettsch, W., & Leufkens, H. (2020). Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study. Frontiers in Pharmacology, 11, Article 594549. https://doi.org/10.3389/fphar.2020.594549
https://dspace.library.uu.nl/bitstream/handle/1874/410887/fphar_11_594549.pdf?sequence=1

2019

Wetenschappelijke publicaties

Wasir, R., Irawati, S., Makady, A., Postma, M., Goettsch, W., Buskens, E., & Feenstra, T. (2019). Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia. PLoS One, 14(2), Article e0212328. https://doi.org/10.1371/journal.pone.0212328
https://dspace.library.uu.nl/bitstream/handle/1874/391178/Use_of_medicine.pdf?sequence=1
Wasir, R., Irawati, S., Makady, A., Postma, M., Goettsch, W., Feenstra, T., & Buskens, E. (2019). The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders. PLoS One, 14(11), Article e0225626. https://doi.org/10.1371/journal.pone.0225626
https://dspace.library.uu.nl/bitstream/handle/1874/391503/journal.pone.0225626.pdf?sequence=1
Wang, S. V., Patterson, O. V., Gagne, J. J., Brown, J. S., Ball, R., Jonsson, P., Wright, A., Zhou, L., Goettsch, W., & Bate, A. (2019). Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate 'Real World' Evidence of Comparative Effectiveness and Safety. Drug Safety, 42(11), 1297-1309. https://doi.org/10.1007/s40264-019-00851-0
https://dspace.library.uu.nl/bitstream/handle/1874/391502/Wang2019_Article_TransparentReportingOnResearch.pdf?sequence=1
Vreman, R. A., Bouvy, J. C., Bloem, L. T., Hövels, A. M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Goettsch, W. G. (2019). Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs. Clinical Pharmacology and Therapeutics, 105(3), 684-691. https://doi.org/10.1002/cpt.1251
https://dspace.library.uu.nl/bitstream/handle/1874/390145/Vreman_et_al_2019_Clinical_Pharmacology_Therapeutics.pdf?sequence=1
Vreman, R. A., Geenen, J. W., Hövels, A. M., Goettsch, W. G., Leufkens, H. G. M., & Al, M. J. (2019). Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied Health Economics and Health Policy, 17(6), 883–893. https://doi.org/10.1007/s40258-019-00496-1
https://dspace.library.uu.nl/bitstream/handle/1874/389459/Vreman2019_Article_PhaseIIIClinicalTrial_BasedEar.pdf?sequence=1
Vreman, R. A., Heikkinen, I., Schuurman, A., Sapede, C., Garcia, J. L., Hedberg, N., Athanasiou, D., Grueger, J., Leufkens, H. G. M., & Goettsch, W. G. (2019). Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions. Value in Health, 22(11), 1275-1282. https://doi.org/10.1016/j.jval.2019.07.007
https://dspace.library.uu.nl/bitstream/handle/1874/389631/unmet_medical.pdf?sequence=1
Makady, A., van Acker, S., Nijmeijer, H., de Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2019). Conditional Financing of Drugs in the Netherlands: Past, Present, and Future-Results From Stakeholder Interviews. Value in Health, 22(4), 399-407. https://doi.org/10.1016/j.jval.2018.11.016
https://dspace.library.uu.nl/bitstream/handle/1874/381079/Conditional_financing.pdf?sequence=1
Schneeweiss, S., Rassen, J. A., Brown, J. S., Rothman, K. J., Happe, L., Arlett, P., Dal Pan, G., Murk, W., Wang, S. V., & Goettsch, W. G. (2019). Graphical Depiction of Longitudinal Study Designs in Health Care Databases. Annals of Internal Medicine, 170(6), 398-406. https://doi.org/10.7326/M18-3079
https://dspace.library.uu.nl/bitstream/handle/1874/379511/schneeweiss.pdf?sequence=1
Makady, A., van Veelen, A., de Boer, A., Hillege, H., Klungel, O. H., & Goettsch, W. (2019). Implementing managed entry agreements in practice: The Dutch reality check. Health Policy, 123(3), 267-274. https://doi.org/10.1016/j.healthpol.2018.09.016
https://dspace.library.uu.nl/bitstream/handle/1874/391037/Implementing.pdf?sequence=1

2018

Wetenschappelijke publicaties

Kalf, R. R. J., Makady, A., ten Ham, R. M. T., Meijboom, K., & Goettsch, W. G. (2018). Use of social media in the assessment of relative effectiveness: Explorative review with examples from oncology. JMIR Cancer, 4(1), Article e11. https://doi.org/10.2196/cancer.7952
https://dspace.library.uu.nl/bitstream/handle/1874/365183/Use_of_Social_Media_in_the_Assessment_of_Relative_Effectiveness.pdf?sequence=2
Makady, A., De Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2018). What is real-world data? A review of definitions based on literature and stakeholder interviews. 410. Abstract from 34th International conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic. https://doi.org/10.1002/pds.4629
Makady, A., Kalf, R. R. J., Ryll, B., Spurrier, G., De Boer, A., Hillege, H., Klungel, O. H., & Goettsch, W. (2018). Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: A feasibility study 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. Health and Quality of Life Outcomes, 16(1), Article 222. https://doi.org/10.1186/s12955-018-1047-z
https://dspace.library.uu.nl/bitstream/handle/1874/373666/s12955_018_1047_z.pdf?sequence=1
Makady, A., Kalf, R., Ryll, B., Spurrier, G., De Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2018). Using social media to collect patient perspectives on quality of life: A feasibility study. Pharmacoepidemiology and Drug Safety, 27, 56. https://doi.org/10.1002/pds.4629
https://dspace.library.uu.nl/bitstream/handle/1874/428137/Pages_from_Pharmacoepidemiology_and_Drug_2018_Abstract_1_.pdf?sequence=1
Makady, A., van Veelen, A., Jonsson, P., Moseley, O., d'Andon, A., de Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2018). Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. PharmacoEconomics, 36(3), 359–368. https://doi.org/10.1007/s40273-017-0596-z
https://dspace.library.uu.nl/bitstream/handle/1874/359058/10.1007_2Fs40273_017_0596_z.pdf?sequence=1

2017

Wetenschappelijke publicaties

Berger, M. L., Sox, H., Willke, R. J., Brixner, D. L., Eichler, H. G., Goettsch, W., Madigan, D., Makady, A., Schneeweiss, S., Tarricone, R., Wang, S. V., Watkins, J., & Daniel Mullins, C. (2017). Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiology and Drug Safety, 26(9), 1033-1039. https://doi.org/10.1002/pds.4297
https://dspace.library.uu.nl/bitstream/handle/1874/428426/Pharmacoepidemiology_and_Drug_2017_Berger_Good_practices_for_real_world_data_studies_of_treatment_and_or_comparative.pdf?sequence=1
Makady, A., Stegenga, H., Ciaglia, A., Debray, T. P. A., Lees, M., Happich, M., Ryll, B., Abrams, K., Thwaites, R., Garner, S., Jonsson, P., & Goettsch, W. (2017). Practical implications of using real-world evidence (RWE) in comparative effectiveness research: Learnings from IMI-GetReal. Journal of Comparative Effectiveness Research, 6(6), 485-490. https://doi.org/10.2217/cer-2017-0044
https://dspace.library.uu.nl/bitstream/handle/1874/428447/cer_2017_0044.pdf?sequence=1
Kristensen, F. B., Lampe, K., Wild, C., Cerbo, M., Goettsch, W., & Becla, L. (2017). The HTA Core Model®-10 Years of Developing an International Framework to Share Multidimensional Value Assessment. Value in Health, 20(2), 244-250. https://doi.org/10.1016/j.jval.2016.12.010
https://dspace.library.uu.nl/bitstream/handle/1874/428449/PIIS1098301516342206.pdf?sequence=1
Berger, M. L., Sox, H., Willke, R. J., Brixner, D. L., Eichler, H.-G., Goettsch, W., Madigan, D., Makady, A., Schneeweiss, S., Tarricone, R., Wang, S. V., Watkins, J., & Mullins, C. D. (2017). Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value in Health, 20(8), 1003-1008. https://doi.org/10.1016/j.jval.2017.08.3019
https://dspace.library.uu.nl/bitstream/handle/1874/428450/PIIS1098301517333533.pdf?sequence=1
Nijmeijer, H., van Veelen, A., De Boer, A., Hillege, H., Klungel, O., Goettsch, W., & Makady, A. (2017). Conditional financing in health technology assessment practice: The Dutch experience. International Journal of Technology Assessment in Health Care, 33, 42-43. https://doi.org/10.1017/S0266462317001660
https://dspace.library.uu.nl/bitstream/handle/1874/428164/op93_conditional_financing_in_health_technology_assessment_practice_the_dutch_experience.pdf?sequence=1
Makady, A., van Veelen, P. A., Jonsson, P. V., Moseley, O., d'Andon, A., De Boer, A., Hillege, J. L., Klungel, O., & Goettsch, W. (2017). Using real-world data (RWD) in health technology assessment (HTA) practice: A comparative study of 5 HTA agencies. Value in Health, 20(9), 401. https://doi.org/10.1016/j.jval.2017.08.017
https://dspace.library.uu.nl/bitstream/handle/1874/359047/1_s2.0_S1098301517303510_main.pdf?sequence=1
Makady, A., de Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2017). What Is Real-World Data (RWD)? A Review of Definitions Based on Literature and Stakeholder Interviews. Value in Health, 20(7), 858-865. https://doi.org/10.1016/j.jval.2017.03.008
https://dspace.library.uu.nl/bitstream/handle/1874/361610/Realworld.pdf?sequence=1
Kleijnen, S., Meneses Leonardo Alves, T., Meijboom, K., Lipska, I., De Boer, A., Leufkens, H. G., & Goettsch, W. G. (2017). The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries. Quality of Life Research, 26(9), 2479-2488. https://doi.org/10.1007/s11136-017-1574-9
https://dspace.library.uu.nl/bitstream/handle/1874/356956/impact.pdf?sequence=1
Makady, A., Ham, R. T., de Boer, A., Hillege, H., Klungel, O., Goettsch, W., & GetReal Workpackage 1 (2017). Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies. Value in Health, 20(4), 520-532. https://doi.org/10.1016/j.jval.2016.12.003
https://dspace.library.uu.nl/bitstream/handle/1874/351489/Policies.pdf?sequence=1

2016

Wetenschappelijke publicaties

Schneeweiss, S., Eichler, H.-G., Garcia-Altes, A., Chinn, C., Eggimann, A.-V., Garner, S., Goettsch, W., Lim, R., Löbker, W., Martin, D., Müller, T., Park, B. J., Platt, R., Priddy, S., Ruhl, M., Spooner, A., Vannieuwenhuyse, B., & Willke, R. J. (2016). Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making. Clinical Pharmacology and Therapeutics, 100(6), 633-646. https://doi.org/10.1002/cpt.512
https://dspace.library.uu.nl/bitstream/handle/1874/428444/Clin_Pharma_and_Therapeutics_2016_Schneeweiss_Real_World_Data_in_Adaptive_Biomedical_Innovation_A_Framework_for.pdf?sequence=1
Kleijnen, S., Lipska, I., Leonardo Alves, T., Meijboom, K., Elsada, A., Vervölgyi, V., d'Andon, A., Timoney, A., Leufkens, H. G., De Boer, A., & Goettsch, W. G. (2016). Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. Annals of Oncology, 27(9), 1768-1775. https://doi.org/10.1093/annonc/mdw233
https://dspace.library.uu.nl/bitstream/handle/1874/336987/Kleijnen_annonc_mdw233.pdf?sequence=1

Overige resultaten

Makady, A., Nijmeijer, H., De Boer, A., Hillege, J. L., Klungel, O., & Goettsch, W. (2016). Implementation of conditional reimbursement schemes in HTA practice: Experiences from the Netherlands. Value in Health, 19(7), A348. https://doi.org/10.1016/j.jval.2016.09.011
Makady, A. A. M. A., ten Ham, R. M. T., de Boer, A., Hillege, H., Klungel, O. H., & Goettsch, W. G. (2016). Policies for use of Real-World Data in Health Technology Assessment: A comparative study of 6 HTA agencies. https://doi.org/10.1016/j.jval.2016.12.003

2015

Wetenschappelijke publicaties

Lampe, K., Pasternack, I., Saarekas, O., Raustia, L., Cleemput, I., Corio, M., Endel, G., Frønsdal, K., Imaz, I., Kleijnen, S., Kristensen, F., Rüther, A., Werkö, S., Cerbo, M., Akiola, L., De Laet, C., Filippi, C., Gasparetto, T., Goettsch, W., ... Vicari, N. (2015). Developing the HTA core model for the online environment. International Journal of Technology Assessment in Health Care, 30(5), 478-487. https://doi.org/10.1017/S0266462314000646
Eichler, H.-G., Baird, L. G., Barker, R., Bloechl-Daum, B., Børlum-Kristensen, F., Brown, J., Chua, R., Del Signore, S., Dugan, U., Ferguson, J., Garner, S., Goettsch, W., Haigh, J., Honig, P., Hoos, A., Huckle, P., Kondo, T., Le Cam, Y., Leufkens, H., ... Hirsch, G. (2015). From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clinical Pharmacology and Therapeutics, 97(3), 234-46. https://doi.org/10.1002/cpt.59
https://research-portal.uu.nl/ws/files/228262802/Clin_Pharma_and_Therapeutics_-_2014_-_Eichler_-_From_adaptive_licensing_to_adaptive_pathways_Delivering_a_flexible.pdf
Kleijnen, S., Toenders, W., de Groot, F., Huic, M., George, E., Wieseler, B., Pavlovic, M., Bucsics, A., Siviero, P. D., van der Graaff, M., Rdzany, R., Kristensen, F. B., & Goettsch, W. (2015). European collaboration on relative effectiveness assessments: What is needed to be successful? Health Policy, 119(5), 569-576. https://doi.org/10.1016/j.healthpol.2015.01.018
https://research-portal.uu.nl/ws/files/228405171/1-s2.0-S0168851015000342-main.pdf
Kleijnen, S., Fathallah, M., van der Linden, M. W., Vancraeynest, P., Dahmani, B., Timoney, A., De Boer, A., Leufkens, H. G., & Goettsch, W. G. (2015). Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments. Value in Health, 18(5), 663-72. https://doi.org/10.1016/j.jval.2015.03.1790
https://dspace.library.uu.nl/bitstream/handle/1874/330029/Joint.pdf?sequence=1

2014

Wetenschappelijke publicaties

Goettsch, W. G., & Enzing, J. (2014). Review: Report of the ISPOR 2012 budget impact analysis good practice II task force. Value in Health, 17(1), 1-2. https://doi.org/10.1016/j.jval.2013.09.003
Berntgen, M., Gourvil, A., Pavlovic, M., Goettsch, W., Eichler, H.-G., & Kristensen, F. B. (2014). Improving the contribution of regulatory assessment reports to health technology assessments--a collaboration between the European Medicines Agency and the European network for Health Technology Assessment. Value in Health, 17(5), 634-41. https://doi.org/10.1016/j.jval.2014.04.006
Kleijnen, S., Pasternack, I., Van de Casteele, M., Rossi, B., Cangini, A., Di Bidino, R., Jelenc, M., Abrishami, P., Autti-Rämö, I., Seyfried, H., Wildbacher, I., & Goettsch, W. G. (2014). Standardized reporting for rapid relative effectiveness assessments of pharmaceuticals. International Journal of Technology Assessment in Health Care, 30(5), 488-96. https://doi.org/10.1017/S0266462314000609
Kleijnen, S., Pasternack, I., Rannanheimo, P., Vuola, J. M., Van de Casteele, M., Bucsics, A., Pulis, I. Z., Di Bidino, R., Sacchini, D., Montilla, S., Abrishami, P., Sammut, S. M., Muscolo, L. A. A., Happonen, P., & Goettsch, W. G. (2014). Piloting international production of rapid relative effectiveness assessments of pharmaceuticals. International Journal of Technology Assessment in Health Care, 30(5), 521-9. https://doi.org/10.1017/S0266462314000622

2013

Wetenschappelijke publicaties

Goettsch, W. (2013). Interview: European collaboration in relative effectiveness assessment: The use of patient registries and development of common guidelines. Journal of Comparative Effectiveness Research, 2(4), 371-373. https://doi.org/10.2217/cer.13.38
Franken, M. G., van Gils, C. W. M., Gaultney, J. G., Delwel, G. O., Goettsch, W., Huijgens, P. C., Steenhoek, A., Punt, C. J. A., Koopman, M., Redekop, W. K., & Uyl-de Groot, C. A. (2013). Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands. European Journal of Cancer, 49(1), 8-16. https://doi.org/10.1016/j.ejca.2012.06.010
Goettsch, W. (2013). European collaboration on relative effectiveness will move into the next phase. Comparative Hepatology, 2(1), 5-6. https://doi.org/10.2217/cer.12.70

2012

Wetenschappelijke publicaties

Kleijnen, S., George, E., Goulden, S., d'Andon, A., Vitré, P., Osińska, B., Rdzany, R., Thirstrup, S., Corbacho, B., Nagy, B. Z., Leufkens, H. G., de Boer, A., & Goettsch, W. G. (2012). Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions. Value in Health, 15(6), 954-60. https://doi.org/10.1016/j.jval.2012.04.010

2011

Wetenschappelijke publicaties

McAfee, A. T., Rodríguez, L. A. G., Goettsch, W. G., González-Pérez, A., Johansson, S., Ming, E. E., Wallander, M. A., & Herings, R. M. C. (2011). Characteristics and drug utilization patterns of new users of rosuvastatin and other statins in four countries (Minerva Cardioangiologica 58, 6, (611-622)). Minerva Cardioangiologica, 59(1).
Hakkaart-Van Roijen, L., Goettsch, W. G., Ekkebus, M., Gerretsen, P., & Stolk, E. A. (2011). The cost-effectiveness of an intensive treatment protocol for severe dyslexia in children. Dyslexia, 17(3), 256-267. https://doi.org/10.1002/dys.436
Grutters, J. P. C., Seferina, S. C., Tjan-Heijnen, V. C. G., van Kampen, R. J. W., Goettsch, W. G., & Joore, M. A. (2011). Bridging trial and decision: a checklist to frame health technology assessments for resource allocation decisions. Value in Health, 14(5), 777-84. https://doi.org/10.1016/j.jval.2011.01.005

2010

Wetenschappelijke publicaties

Mcafee, A. T., Garciá-Rodríguez, L. A., Goettsch, W. G., González-Pérez, A., Johansson, S., Ming, E. E., Wallander, M. A., & Herings, R. M. C. (2010). Characteristics and drug utilization patterns of new users of rosuvastatin and other statins in four countries. Minerva Cardioangiologica, 58(6), 611-622.

2009

Wetenschappelijke publicaties

Quentin, F., Carbonneil, C., Moty-Monnereau, C., Berti, E., Goettsch, W., & Lee-Robin, S. H. (2009). Web-based toolkit to facilitate European collaboration on evidence generation on promising health technologies. International Journal of Technology Assessment in Health Care, 25(SUPPL.S2), 68-74. https://doi.org/10.1017/S0266462309990705

2007

Wetenschappelijke publicaties

Penning-Van Beest, F. J. A., Termorshuizen, F., Goettsch, W. G., Klungel, O. H., Kastelein, J. J. P., & Herings, R. M. C. (2007). Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: A cohort study. European Heart Journal, 28(2), 154-159. https://doi.org/10.1093/eurheartj/ehl391
Goettsch, W. G., de Jong, R. B., Kramarz, P., & Herings, R. M. C. (2007). Developments of the incidence of osteoporosis in The Netherlands: A PHARMO study. Pharmacoepidemiology and Drug Safety, 16(2), 166-172. https://doi.org/10.1002/pds.1245
Goettsch, W. G., Sukel, M. P. P., van der Peet, D. L., van Riemsdijk, M. M., & Herings, R. M. C. (2007). In-hospital use of opioids increases rate of coded postoperative paralytic ileus. Pharmacoepidemiology and Drug Safety, 16(6), 668-674. https://doi.org/10.1002/pds.1338

2006

Wetenschappelijke publicaties

Breekveldt-Postma, N., Siiskonen, S., Goettsch, W., & Herings, R. (2006). Therapietrouw hoog maar niet vanzelfsprekend bij tumorpatiënten: Vier op de vijf trouw aan imatinib. Pharmaceutisch Weekblad, 141(16), 550-551.
Penning-van Beest, F. J. A., Goettsch, W. G., Erkens, J. A., & Herings, R. M. C. (2006). Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis. Clinical Therapeutics, 28(2), 236-242. https://doi.org/10.1016/j.clinthera.2006.01.002
Goettsch, W. G., Bouwes Bavinck, J. N., & Hering, R. M. C. (2006). Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. Journal of the European Academy of Dermatology and Venereology, 20(7), 834-839. https://doi.org/10.1111/j.1468-3083.2006.01657.x
Goettsch, W. G., Heintjes, E. M., Kastelein, J. J. P., Rabelink, T. J., Johansson, S., & Herings, R. M. C. (2006). Results from a rosuvastatin historical cohort study in more than 45000 Dutch statin users, a PHARMO study. Pharmacoepidemiology and Drug Safety, 15(7), 435-443. https://doi.org/10.1002/pds.1278
Johansson, S., Ming, E. E., Wallander, M. A., García Rodríguez, L. A., Herings, R. M. C., Goettsch, W. G., González-Pérez, A., McAfee, A. T., & Walker, A. M. (2006). Rosuvastatin safety: A comprehensive, international pharmacoepidemiology programme. Pharmacoepidemiology and Drug Safety, 15(7), 454-461. https://doi.org/10.1002/pds.1260
Van Den Boogaard, C. H. A., Breekveldt-Postma, N. S., Borggreve, S. E., Goettsch, W. G., & Herings, R. M. C. (2006). Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: A database analysis study. Current Medical Research and Opinion, 22(9), 1757-1764. https://doi.org/10.1185/030079906X132370
De Jong, R. B., Goettsch, W. G., & Herings, R. M. C. (2006). Onjuiste startbehandeling van secundaire intra-abdominale infecties: Klinisch falen doet kosten stijgen. Pharmaceutisch Weekblad, 141(50), 1592-1593.
ten Berg, M. J., Goettsch, W. G., van den Boom, G., Smout, A. J. P. M., & Herings, R. M. C. (2006). Quality of life of patients with irritable bowel syndrome is low compared to others with chronic disesaes. European Journal of Gastroenterology and Hepatology, 18, 475-481.
https://dspace.library.uu.nl/bitstream/handle/1874/27462/berg_06_qualityofLifeofpatients.pdf?sequence=1
van de Garde, E. M. W., Souverein, P. C., van den Bosch, J. M. M., Deneer, V. H. M., Goettsch, W. G., & Leufkens, H. G. M. (2006). Prior outpatient antibacterial therapy as prognostic factor for mortality in hospitalized pneumonia patients. Respiratory Medicine, 100(8), 1342-1348. https://doi.org/10.1016/j.rmed.2005.11.024

Overige resultaten

van der Bij, S., Breekveldt-Postma, N. S., Goettsch, W. G., Chen, C., Erkens, J. A., & Herings, R. M. C. (2006). Adherence with Proton Pump Inhibitors and Non-Selective NSAIDs and Impact on Gastrointestinal Hospitalizations. S293. Abstract from Unknown event, Asilomar, USA.
Sukel, M., Goettsch, W. G., Borggreve, S. E., Chen, C., Kramarz, P., Lilliu, H., & Herings, R. M. C. (2006). Assessment of Analgesic Treatment Switch Patterns Post-Rofecoxib Withdrawal. S45. Abstract from Unknown event, Asilomar, USA.
Penning-van Beest, F. J. A., Goettsch, W. G., Klungel, O. H., Kastelein, J. J. P., & Herings, R. M. C. (2006). Adherence to Evidence-Based Statin Guidlines Reduces Risk for Acute Myocardial Infarction by 40%. S293. Abstract from Unknown event, Asilomar, USA.
Goettsch, W. G., Heintjes, E., Kastelein, J. J. P., Johansson, S., & Herings, R. M. C. (2006). Rosuvastatin's Safety Profile Is Comparable to That of Other Marketed Statins: Results from a Historical Cohort Study in More Than 45,000 Dutch Statin Users. S248. Abstract from Unknown event, Asilomar, USA.
van den Boogaard, C. H. A., Breekveldt-Postma, N. S., Goettsch, W. G., Middelhoven, H., Lynch, N. O., & Herings, R. M. C. (2006). The Risk of Osteoporotic Fractures in Clinical Practice Is Reduced with Persistent Bisposphonate Use. S175. Abstract from Unknown event, Asilomar, USA.

2005

Wetenschappelijke publicaties

Goettsch, W. G., Termorshuizen, F., & Herings, R. M. C. (2005). Helft patiënten bereikt streefwaarden niet in de dagelijkse praktijk: Statinen onvoldoende effectief. Pharmaceutisch Weekblad, 140(24), 814-815.
Sturkenboom, M. C. J. M., Goettsch, W. G., Picelli, G., Veld, B., Yin, D. D., Jong, R. B., Go, P. M. N. Y. H., & Herings, R. M. C. (2005). Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. British Journal of Clinical Pharmacology, 60(4), 438-443.
https://dspace.library.uu.nl/bitstream/handle/1874/11832/herings_05_inappropriateinitialtreatmentofsecondaryintra_abdomin.pdf?sequence=2
Goettsch, W. G., Bos, S. D., Breekveldt-Postma, N. S., Casparie, M., Herings, R. M. C., & Hogendoorn, P. C. (2005). Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. European Journal of Cancer, 41(18), 2868-2872.
https://dspace.library.uu.nl/bitstream/handle/1874/11837/herings_05_incidenceofgastrointestinalstromaltumours.pdf?sequence=2

Vakpublicaties

Goettsch, W. G., Jong, R. B., & Herings, R. M. C. (2005). Driedaagse kuren nitrofurantoïne. Te kort voor de behandeling van urineweginfecties. Pharmaceutisch Weekblad, 15, 508-509.
https://dspace.library.uu.nl/bitstream/handle/1874/11833/herings_05_driedaagsekurennitrofurantoine.pdf?sequence=2
Penning-van Beest, F. J. A., Goettsch, W. G., & Herings, R. M. C. (2005). Onderbehandeling na fractuur. Pharmaceutisch Weekblad, 22, 751.
https://dspace.library.uu.nl/bitstream/handle/1874/11831/herings_05_onderbehandelingnafractuur.pdf?sequence=2

Overige resultaten

ten Berg, M. J., Goettsch, W. G., Smet, P. A. G. M., & Herings, R. M. C. (2005). A Risk Scoring Algorithm for Determining the Risk for Developing Gastrointestinal Toxicity during NSAID-Exposure from Pharmacy Data. S139. Abstract from Unknown event, Asilomar, USA.
ten Berg, M. J., Goettsch, W. G., Siiskonen, S. J., van den Boom, G., Smout, A. J. P. M., & Herings, R. M. C. (2005). Burden of illness is highest in patients with severe pain symptoms. Abstract from Unknown event, Asilomar, USA.
Goettsch, W. G., van der Peet, D., Riemsdijk, M. M., & Herings, R. M. C. (2005). In-Hospital Opioid Use in Daily Practice Is Strongly Associated with the Occurrence of Coded Postoperative Paralytic Ileus after Digestive or Abdominal Surgery. S67. Abstract from Unknown event, Asilomar, USA.
Sukel, M., Goettsch, W. G., Temorshuizen, F., & Herings, R. M. C. (2005). Use of Rosuvastatin (Crestor®) after Introduction on to the Dutch Market. S99. Abstract from Unknown event, Asilomar, USA.
ten Berg, M. J., Goettsch, W. G., van den Boom, G., Smout, A. J. P. M., & Herings, R. M. C. (2005). Burden of illnes of IBS patients in the Netherlands. Abstract from Unknown event, Asilomar, USA.
Jong, R. B., Breekveldt-Postma, N. S., Goettsch, W. G., & Herings, R. M. C. (2005). Cardiovasular Risk factors at Baseline in Users of Coxibs Compared to Users of NSAIDs. S164. Abstract from Unknown event, Asilomar, USA.
ten Berg, M. J., Goettsch, W. G., de Smet, P. G. A. M., & Herings, R. M. C. (2005). Evaluation of an Automated Risk Score for Determining the Risk for NSAID-Related Gastrointestinal Events Using Pharmacy Data. S25. Abstract from Unknown event, Asilomar, USA.

2004

Wetenschappelijke publicaties

Herings, R. M. C., & Goettsch, W. G. (2004). Inadequate Prevention of NSAID-Induced Gastrointestinal Events. Annals of Pharmacotherapy, 38(5), 760-763. https://doi.org/10.1345/aph.1D068
Goettsch, W. G., Janknegt, R., & Herings, R. M. C. (2004). Increased treatment failure after 3-days' courses of nitrofurantoin and trimethoprim for urinary tract infections in women: A population-based retrospective cohort study using the PHARMO database. British Journal of Clinical Pharmacology, 58(2), 184-189. https://doi.org/10.1111/j.1365-2125.2004.02106.x
Goettsch, W. G., Yin, D. D., Alemao, E., Klungel, O. H., Stalenhoef, A. F., & Herings, R. M. C. (2004). Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Current Medical Research and Opinion, 20(7), 1025-1033.
https://dspace.library.uu.nl/bitstream/handle/1874/11654/klungel_04_statins_are_less_effective_via_pharma_statins.pdf?sequence=2
Mantel-Teeuwisse, A. K., Goettsch, W. G., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2004). Long term persistence with statin treatment in daily medical practice. Heart, 90(9), 1065-1066. https://doi.org/10.1136/hrt.2003.026187
https://dspace.library.uu.nl/bitstream/handle/1874/328801/boer_04_MantelLongtermpersistencewithstatintreatment.pdf?sequence=1
Goettsch, W. G., van den Boom, G., Breekveldt, N. S., Smout, A. J. P. M., & Herings, R. M. C. (2004). Treatment patterns and health care costs of mebeverine-treated IBS patiens: a case-control study. Pharmacoepidemiology and Drug Safety, 13, 803-810.

Overige resultaten

Herings, R. M. C., & Goettsch, W. G. (2004). Inadequate Prevention of NSAID-Induced Gastro-intestinal Events among Long-Term Users of NSAIDs. S54. Abstract from Unknown event, Asilomar, USA.
Panneman, M. J. M., Goettsch, W. G., Kramarz, P., & Herings, R. M. C. (2004). Epidemiology of Osteoporosis in the Netherlands (1992-2002). S297. Abstract from Unknown event, Asilomar, USA.
Goettsch, W. G., de berg, M. J., & Herings, R. M. C. (2004). Characterization of IBS and Non-IBS Patients Using Mebeverine in Daily Practice. S228. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Goettsch, W. G., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2004). Determinants of persistence with statin use in daily medical practice. 361. Abstract from Unknown event, Asilomar, USA.
Goettsch, W. G., Tangelder, M. J. D., & Herings, R. M. C. (2004). Use of Platelet Aggregation Inhibitors after Ischemic Vascular Events in the Netherlands. S103. Abstract from Unknown event, Asilomar, USA.

2003

Wetenschappelijke publicaties

Goettsch, WG., van den Boom, G., Breekveldt, N., Smout, A., & Herings, RMC. (2003). Treatment patterns and health care costs of mebeverine-treated IBS patients: A case-control study. Value in Health, 6(3), 248-248. https://doi.org/10.1016/S1098-3015(10)63973-3
Termorshuizen, F., Hogewoning, A. A., Bouwes Bavinck, J. N. B., Goettsch, W. G., de Fijter, J. W., & van Loveren, H. (2003). Skin infections in renal transplant recipients and the relation with solar ultraviolet radiation. Clinical Transplantation, 17(6), 522-527. https://doi.org/10.1046/j.0902-0063.2003.00099.x
Pannerman, M. J., Goettsch, W. G., Kramarz, P., & Herings, R. M. C. (2003). The costs of benzodiazepine-associated hospital-treated fall injuries in the EU: a PHARMO study. Drugs & Aging, 20(11), 833-839.
https://dspace.library.uu.nl/bitstream/handle/1874/29445/herings_03_thecostsofbenzodiazepine-associated.pdf?sequence=1

Overige resultaten

Goettsch, W. G., van den Boom, G., Breekveldt, N. S., Smout, A. J. P. M., & Herings, R. M. C. (2003). Medical Resource Use and Associated Health Care Costs in Mebeverine-Treated IBS Patients. S94-S95. Abstract from Unknown event, Asilomar, USA.
Panneman, M. J. M., Goettsch, W. G., Kramarz, P., & Herings, R. M. C. (2003). An Assessment of the Economic Burden of Benzodiazepine-Associated Falls in the European Union. S69. Abstract from Unknown event, Asilomar, USA.
Goettsch, W. G., Yin, D. D., Alemao, E., & Herings, R. M. C. (2003). Real-Life Treatment Patterns of Patients with Hypercholesterolemia in the Netherland 1991-2001. S76-S77. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Goettsch, W. G., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2003). Discontinuation of Statin Use in Daily Medical Practice. S76. Abstract from Unknown event, Asilomar, USA.
de Boer, A., Herings, R. M. C., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Klungel, O. H. (2003). Discontinuation of Satin Use in Daily Medical Practice. S76. Abstract from Unknown event, Asilomar, USA.

2002

Wetenschappelijke publicaties

Maas, J., Termorshuizen, F., Geskus, R. B., Goettsch, W., Coutinho, R. A., Miedema, F., & Van Loveren, H. (2002). Amsterdam cohort study on HIV and AIDS: Impact of exposure to UVR as estimated by means of a 2-year retrospective questionnaire on immune parameters in HIV positive males. International Journal of Hygiene and Environmental Health, 205(5), 373-377. https://doi.org/10.1078/1438-4639-00171
Bronzwaer, S. L. A. M., Cars, O., Udo Buchholz, S. M., Goettsch, W., Veldhuijzen Jacob L Kool, I. K., Sprenger, M. J. W., & Degener, J. E. (2002). A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerging Infectious Diseases, 8(3), 278-282. https://doi.org/10.3201/eid0803.010192
Bronzwaer, S., Buchholz, U., Courvalin, P., Snell, J., Cornaglia, G., de Neeling, A., Aubry-Damon, H., Degener, J., Mittermayer, H., Koller, W., Goossens, H., van Loock, F., Markova, B., Urbaskova, P., Sørensen, T. L., Monnet, D., Huovinen, P., Lyytikäinen, O., Courvalin, P., ... Wale, M. (2002). Comparability of antimicrobial susceptibility test results from 22 European countries and Israel: An external quality assurance exercise of the European antimicrobial resistance surveillance system (EARSS) in collaboration with the United Kingdom national external quality assurance scheme (UK NEQAS). Journal of Antimicrobial Chemotherapy, 50(6), 953-964. https://doi.org/10.1093/jac/dkf231

2001

Wetenschappelijke publicaties

Hogewoning, AA., Goettsch, W., van Loveren, H., de Fijter, JW., Vermeer, BJ., & Bavinck, JNB. (2001). Skin infections in renal transplant recipients. Clinical Transplantation, 15(1), 32-38. https://doi.org/10.1034/j.1399-0012.2001.150106.x
De Neeling, A. J., Overbeek, B. P., Horrevorts, A. M., Ligtvoet, E. E. J., & Goettsch, W. G. (2001). Antibiotic use and resistance of Streptococcus pneumoniae in The Netherlands during the period 1994-1999. Journal of Antimicrobial Chemotherapy, 48(3), 441-444. https://doi.org/10.1093/jac/48.3.441

2000

Wetenschappelijke publicaties

Goettsch, W., Van Pelt, W., Nagelkerke, N., Hendrix, M. G. R., Buiting, A. G. M., Petit, P. L., Sabbe, L. J. M., Van Griethuysen, A. J. A., & De Neeling, A. J. (2000). Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in The Netherlands. Journal of Antimicrobial Chemotherapy, 46(2), 223-228. https://doi.org/10.1093/jac/46.2.223
Goettsch, W., Bronzwaer, S. L. A. M., de Neeling, A. J., Wale, M. C. J., Aubry-Damon, H., Olsson-Liljequist, B., Sprenger, M. J. W., & Degener, J. E. (2000). Standardization and quality assurance for antimicrobial resistance surveillance of Streptococcus pneumoniae and Staphylococcus aureus within the European Antimicrobial Resistance Surveillance System (EARSS). Clinical Microbiology and Infection, 6(2), 59-63. https://doi.org/10.1046/j.1469-0691.2000.00027.x

1999

Wetenschappelijke publicaties

Goettsch, W., & Degener, JE. (1999). Health council report on antibiotic growth promoters. Tijdschrift voor Diergeneeskunde, 124(9), 285-286.
Goettsch, W., & Degener, JE. (1999). Health council report 'Antimicrobial growth promoters'. Tijdschrift voor Diergeneeskunde, 124(5), 142-144.
Goettsch, W., De Neeling, A. J., Bronzwaer, S., Greijmans, M., Bootsma, P. A., & Sprenger, M. J. W. (1999). Nederland neemt initiatief tot oprichting van het European Antimicrobial Resistance Surveillance System (EARSS). Nederlands Tijdschrift voor Medische Microbiologie, 7(1), 9-13.
Goettsch, W., De Graaf, R., Dorigo-Zetsma, J. W., Van Zessen, G., & Houweling, H. (1999). Broader vaccination of expatriates against HBV infection: Do we reach those at highest risk? International Journal of Epidemiology, 28(6), 1161-1166. https://doi.org/10.1093/ije/28.6.1161
Talsma, E., Goettsch, W. G., Nieste, H. L. J., Schrijnemakers, P. M., & Sprenger, M. J. W. (1999). Resistance in Campylobacter species: Increased resistance to fluoroquinolones and seasonal variation. Clinical Infectious Diseases, 29(4), 845-848. https://doi.org/10.1086/520447
Goettsch, W. G., Goossens, H., De Neeling En, A. J., & Sprenger, M. J. W. (1999). Infecties en bacteriele resistentie in de open bevolking. Nederlands Tijdschrift voor Geneeskunde, 143(25), 1296-1299.
Goettsch, W., Garssen, J., De Gruijl, F. R., Dortant, P., & Van Loveren, H. (1999). Methods for exposure of laboratory animals to ultraviolet radiation. Laboratory Animals, 33(1), 58-67. https://doi.org/10.1258/002367799780578507

1998

Wetenschappelijke publicaties

Goettsch, W., Hurks, H. M. H., Garssen, J., Mommaas, A. M., Slob, W., Hoekman, J., Pierik, F., Roholl, P. J. M., & Van Loveren, H. (1998). Comparative immunotoxicology of ultraviolet B exposure I. Effects of in vitro and in situ ultraviolet B exposure on the functional activity and morphology of Langerhans cells in the skin of different species. British Journal of Dermatology, 139(2), 230-238. https://doi.org/10.1046/j.1365-2133.1998.02359.x

1997

Wetenschappelijke publicaties

Garssen, J., Goettsch, W., deGruijl, F., Slob, W., & VanLoveren, H. (1997). Risk assessment of UVB effects on resistance to infectious diseases (vol 64, pg 269, 1996). Photochemistry and Photobiology, 65(6), 1045-1045.
VanLoveren, H., Goettsch, W., Slob, W., & Garssen, J. (1997). Risk assessment for the harmful effects of immunotoxic agents on the immunological resistance to infectious diseases: Ultraviolet light as an example. Toxicology, 119(1), 59-64. https://doi.org/10.1016/S0300-483X(96)03597-4
Steerenberg, PA., Garssen, J., Dortant, P., vandeVliet, H., Geerse, L., Verlaan, APJ., Goettsch, W., Sontag, Y., Norval, M., Gibbs, NK., BuenodeMesquita, HB., & VanLoveren, H. (1997). Quercetin prevents UV-induced local immunosuppression, but does not affect UV-induced tumor growth in SKH-1 hairless mice. Photochemistry and Photobiology, 65(4), 736-744. https://doi.org/10.1111/j.1751-1097.1997.tb01918.x
Steerenberg, P. A., Garssen, J., Dortant, P. M., Van Der Vliet, H., Geerse, E., Verlaan, A. P. J., Goettsch, W. G., Sontag, Y., Bueno-de-Mesquita, H. B., & Van Loveren, H. (1997). The effect of oral quercetin on UVB-induced tumor growth and local immunosuppression in SKH-1. Cancer Letters, 114(1-2), 187-189. https://doi.org/10.1016/S0304-3835(97)04659-4

1996

Wetenschappelijke publicaties

Garssen, J., Goettsch, W., De Gruijl, F., Slob, W., & Van Loveren, H. (1996). Risk assessment of UVB effects on resistance to infectious diseases. Photochemistry and Photobiology, 64(2), 269-274. https://doi.org/10.1111/j.1751-1097.1996.tb02457.x
Goettsch, W., Garssen, J., de Klerk, A., Herremans, T. M., Dortant, P., de Gruijl, F. R., & Van Loveren, H. (1996). Effects of ultraviolet-B exposure on the resistance to Listeria monocytogenes in the rat. Photochemistry and Photobiology, 63(5), 672-679.
Van Loveren, H., Goettsch, W., Slob, W., & Garssen, J. (1996). Risk assessment for the harmful effects of UVB radiation on the immunological resistance to infectious diseases. Archives of toxicology. Supplement. = Archiv für Toxikologie. Supplement, 18, 21-28.
Goettsch, W., Garssen, J., De Gruijl, F. R., & Van Loveren, H. (1996). UVB-induced decreased resistance to Trichinella spiralis in the rat is related to impaired cellular immunity. Photochemistry and Photobiology, 64(3), 581-585.

1995

Wetenschappelijke publicaties

Garssen, J., Goettsch, W., Sonntag, Y., De Gruijl, F., & Van Loveren, H. (1995). UVB can affect the immune system resulting in decreased resistance to infections and tumors. Studies in Environmental Science, 65(PART B), 1005-1009. https://doi.org/10.1016/S0166-1116(06)80125-1
Garssen, J., Van der Vliet, H., De Klerk, A., Goettsch, W., Dormans, J. A. M. A., Bruggeman, C. A., Osterhaus, A. D. M. E., & Van Loveren, H. (1995). A rat cytomegalovirus infection model as a tool for immunotoxicity testing. European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section, 292(3), 223-231. https://doi.org/10.1016/0926-6917(95)90026-8

1994

Wetenschappelijke publicaties

Goettsch, W., Garssen, J., De Gruijl, F. R., & Van Loveren, H. (1994). Effects of UV-B on the resistance against infectious diseases. Toxicology Letters, 72(1-3), 359-363. https://doi.org/10.1016/0378-4274(94)90049-3
Goettsch, W., Garssen, J., Deijns, A., De Gruijl, F. R., & Van Loveren, H. (1994). UV-B exposure impairs resistance to infection by Trichinella spiralis. Environmental Health Perspectives, 102(3), 298-301. https://doi.org/10.1289/ehp.94102298
Goettsch, W., Garssen, J., Hurks, M. H., De Gruijl, F. R., & Van Loveren, H. (1994). Effects of in vitro exposure to ultraviolet radiation on the functional activity of lymphocytes, with emphasis on susceptibility of different species. Photochemistry and Photobiology, 60(4), 373-379.

1993

Wetenschappelijke publicaties

GARSSEN, J., GOETTSCH, W., DEIJNS, A., VANDERVLIET, H., PIERIK, F., DEGRUIJL, FR., & VANLOVEREN, H. (1993). Uv-b Suppresses Resistance Against Systemic (not Skin-related) Infections. Journal of Investigative Dermatology, 100(4), 475-475.
Goettsch, W., Garssen, J., De Gruijl, F. R., & Van Loveren, H. (1993). UV-B and the immune system. A review with special emphasis on T cell-mediated immunity. Thymus, 21(2), 93-114.

1992

Wetenschappelijke publicaties

Goettsch, W., Hatori, Y., & Sharma, R. P. (1992). Adjuvant activity of all-trans-retinoic acid in C57Bl/6 mice. International Journal of Immunopharmacology, 14(2), 143-150. https://doi.org/10.1016/0192-0561(92)90024-F

Direct naar

Diensten

Over de UU